Nattawat Klomjit, MD, shares insights on managing IgA nephropathy and C3 glomerulopathy, including innovative drugs that target kidney inflammation and proteinuria.
Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a ...
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...
The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) The planned clinical study will be executed ...
20h
Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for ...
Credit: Thinkstock Investigators attending ASN’s Kidney Week 2024 reported progress on a number of IgA nephropathy drug ...
In a new study, researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs ...
Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effectMarks ...
U.S. policies that fix the IRA, strengthen patents, and incentivize antimicrobial research could help hasten new medicines ...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...
Aerobic exercise has been linked with Parkinson's disease progression and risk. ( Washington Post) Air purifiers in residential aged-care facilities did not reduce the incidence of acute respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback